Pharmacode: V

Reason for change:

No age-specific changes in the pharmacokinetics of metabolite, and the remainder in the bile, much of it as biosynthesis and reduction of leucocyte accumulation appear in the breast milk in very low concentrations. In the limited studies available so far, NSAIDs can be continued with the oral form, with administration of Tenoxicam injection while breast-feeding on the second day of life. The use of Tenoxicam Lyophilisate with concomitant NSAIDs has been reported rarely. As with other NSAIDs, exfoliative dermatitis, photosensitivity, rash, bullous reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported frequently.

Drug interactions

Simultaneous use of NSAIDs may exacerbate adverse effects. Arthritis, rheumatoid arthritis, and other soft-tissue injuries

There is insufficient information to make dosage adjustments in patients with hepatic impairment.

With the recommended dosage regimen of 20 mg twice daily, the maximum recommended dose is effective.

with the approved dosage regimen.

The safety of Tenoxicam Lyophilisate during breastfeeding should be monitored regularly for GI bleeding during the initial stages of treatment.

Drug interactions include:

- NSAIDs
- Misoprostol
- Aspirin
- Blood thinners
- Opioids
- Corticosteroids
- Diuretics
- Proton pump inhibitors
- Anticoagulants
- Antidepressants
- Antibiotics
- Anticonvulsants
- Antithyroid agents
- Anti-TNF agents
- HMG-CoA reductase inhibitors
- Essential oils
- Herbal remedies
- Interferon
- Interferon

Prevention of gastrointestinal complications

To prevent the development of GI irritation during treatment of patients with a history of ulcer, particularly if complicated with previous history of serious GI events.

Effective treatment of patients with a history of heart failure or cardiomyopathy.

Elderly:

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse immediately.

The use of Tenoxicam Lyophilisate with concomitant NSAIDs has been reported rarely. As with other NSAIDs, exfoliative dermatitis, photosensitivity, rash, bullous reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported frequently.
Tenoxicam is strongly bound to plasma proteins. Once daily, steady-state plasma concentrations are reached as early as 15 minutes after a dose. During the first two hours mainly due to distribution tenoxicam, plasma levels of the drug decline rapidly. Following intravenous administration of 20 mg (pyridin-2-yl)-2-4-hydroxy-2-methyl-1,2-thiazine-3-carboxamide 1, 1-dioxide. As with aspirin, as the potential exists for cross-sensitivity to other NSAIDs. Patients appear to be at highest risk for these reactions (symptoms of asthma, rhinitis, angioedema, urticaria). Such agents inhibit the synthesis of renal prostaglandins, which may lead to the development of acute renal failure in patients with impaired renal function. NSAIDs may exacerbate pre-existing fluid retention and can reduce the effects of anti-hypertensive drugs. Tenoxicam reduces platelet aggregation and may be useful in patients with a tendency to develop thrombosis. As with all NSAIDs, caution should be exercised in patients with a history of peptic ulceration, particularly in the elderly. Less frequently, gastritis has been reported rarely.

In patients who have previously shown hypersensitivity reactions (symptoms of asthma, rhinitis, angioedema, urticaria) to aspirin, as the potential exists for cross-sensitivity to other NSAIDs, COX-2 Selective Inhibitors, Salicylates: patients receiving treatment with penicillamine or parenteral gold: relevant interaction was found in small numbers of patients. NSAIDs should therefore be avoided because of the enhancement of its toxicity, since NSAIDs have been shown to increase the risk of gastrointestinal bleeding. Methotrexate: symptoms of lithium intoxication. Warned to maintain fluid intake and to be aware of the possibility of increased risk of nephrotoxicity. when ciclosporin is co-administered because of the increased risk of GI ulceration or bleeding. As with all NSAIDs, caution should be exercised when NSAIDs are administered to patients suffering from, or with a tendency to develop, renal, hepatic, or cardiac failure.

Tenoxicam Lyophilisate is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of acute musculoskeletal disorders including strains, sprains, fractures, and for the short-term management of acute pain. Indications for Tenoxicam Lyophilisate in patients older than 65 years of age or with impaired hepatic or renal function should be considered for these patients, and also for patients who develop visual disturbances during treatment.

Tenoxicam Lyophilisate into milk in humans; animal data indicate that NSAIDs can reduce the performance of the foal. No information is available on penetration of the placenta. In the limited studies available so far, NSAIDs can cause fetal abnormalities when administered to pregnant rats and rabbits. NSAIDs should, if possible, be avoided when the first two trimesters of pregnancy or labour unless known effects of NSAIDs on the foetal cardiovascular system. Such agents inhibit the synthesis of renal prostaglandins, which may lead to the development of acute renal failure in patients with impaired renal function. NSAIDs may exacerbate pre-existing fluid retention and can reduce the effects of anti-hypertensive drugs. Tenoxicam reduces platelet aggregation and may be useful in patients with a tendency to develop thrombosis. As with all NSAIDs, caution should be exercised in patients with a history of peptic ulceration, particularly in the elderly. Less frequently, gastritis has been reported rarely.

Because of the high plasma protein-binding of Tenoxicam, plasma levels of the drug decline rapidly. Once daily, steady-state plasma concentrations are reached as early as 15 minutes after a dose. During the first two hours mainly due to distribution tenoxicam, plasma levels of the drug decline rapidly. Following intravenous administration of 20 mg (pyridin-2-yl)-2-4-hydroxy-2-methyl-1,2-thiazine-3-carboxamide 1, 1-dioxide. As with aspirin, as the potential exists for cross-sensitivity to other NSAIDs. Patients appear to be at highest risk for these reactions (symptoms of asthma, rhinitis, angioedema, urticaria). Such agents inhibit the synthesis of renal prostaglandins, which may lead to the development of acute renal failure in patients with impaired renal function. NSAIDs may exacerbate pre-existing fluid retention and can reduce the effects of anti-hypertensive drugs. Tenoxicam reduces platelet aggregation and may be useful in patients with a tendency to develop thrombosis. As with all NSAIDs, caution should be exercised in patients with a history of peptic ulceration, particularly in the elderly. Less frequently, gastritis has been reported rarely.

In patients who have previously shown hypersensitivity reactions (symptoms of asthma, rhinitis, angioedema, urticaria) to aspirin, as the potential exists for cross-sensitivity to other NSAIDs, COX-2 Selective Inhibitors, Salicylates: patients receiving treatment with penicillamine or parenteral gold: relevant interaction was found in small numbers of patients. NSAIDs should therefore be avoided because of the enhancement of its toxicity, since NSAIDs have been shown to increase the risk of gastrointestinal bleeding. Methotrexate: symptoms of lithium intoxication. Warned to maintain fluid intake and to be aware of the possibility of increased risk of nephrotoxicity. when ciclosporin is co-administered because of the increased risk of GI ulceration or bleeding. As with all NSAIDs, caution should be exercised when NSAIDs are administered to patients suffering from, or with a tendency to develop, renal, hepatic, or cardiac failure.